Biotech Values

[10nisman]

RE: Apixaban fails in ACS
Dew - Now that Apixaban has failed, any idea on what potential size partnership MNTA can ink for M118 if it paid for 15% of development costs? Something in the ballpark of $50-100 million upfront, $250-350 million in milestones and 10-15% of sales??? If MNTA choose to sell M118 what do you think it could conservative be sold for --- $150-200 million and some low percentage of sales (2-3%)? Just trying to get my hands around a potental value of M118.

Thanks,
10nis

Apixaban:
Terms of the apixaban agreement include an upfront payment of $250 million by Pfizer to Bristol-Myers Squibb. Pfizer will fund 60% of all planned development costs effective and Bristol-Myers Squibb will fund 40%. Bristol-Myers Squibb may also receive additional payments of up to $750 million based on milestones. The companies will jointly develop the clinical and marketing strategy of apixaban.